PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)

NCT01445899 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

258

Enrollment

INDUSTRY

Sponsor class

Conditions

Choroidal Neovascularization
Diabetic Retinopathy
Diabetic Macular Edema

Interventions

DRUG: PF-04523655 (Stratum I)
DRUG: ranibizumab
DRUG: PF-04523655 (Stratum II)

Sponsor

Quark Pharmaceuticals